The worlds #1 website for end of day & historical stock data
wide range of exchanges, data formats, tools and services
API
NEW
HISTORICAL DATA
SYMBOL LISTS
MEMBERSHIP
REGISTER
LOG IN
Toggle navigation
HOME
Home Page
Download
Symbol Lists
Quote & Chart
Symbol Changes
Splits
Dividends
PRODUCTS & SERVICES
Membership Levels
Conversion Utility
API Service
Data Client
Historical Data
Fundamental Data
Commercial Feeds
Web Service
HOW TO
Advanced Get
AIQ
AMIBroker
EzyChart
MetaStock
OmniTrader
SuperCharts
TradeStation
SUPPORT
FAQ
Data Formats
Data Quality
Forgotten Password
Submit a Support Request
ABOUT
About Us
Contact Us
Terms & Conditions
Privacy Policy
Useful Links
MY ACCOUNT
Downloads
Account Details
API
Buy Historical Data
Billing History
Data Format
Daily Emails
Watchlists
FRA, I54: BIOCYTOGEN PHARMA. H YC1
03 Sep 2025
LAST:
2.740
CHANGE:
0.15
OPEN:
2.720
HIGH:
2.740
ASK:
0.000
VOLUME:
1.1K
CHG(%):
5.79
PREV:
2.590
LOW:
2.720
BID:
0.000
CHART
Period:
End of Day
Weekly
Monthly
Yearly
RECENT END OF DAY PRICES
Date
Open
High
Low
Close
Volume
03 Sep 25
2.720
2.740
2.720
2.740
1.1K
02 Sep 25
2.590
2.590
2.590
2.590
1.1K
01 Sep 25
2.735
2.735
2.690
2.710
1.1K
29 Aug 25
2.460
2.475
2.460
2.470
1.1K
28 Aug 25
2.335
2.335
2.335
2.335
0
27 Aug 25
2.335
2.335
2.335
2.335
1.1K
26 Aug 25
2.485
2.490
2.485
2.490
1.1K
25 Aug 25
2.715
2.715
2.715
2.715
0
22 Aug 25
2.715
2.715
2.695
2.715
108
21 Aug 25
2.410
2.410
2.355
2.360
108
COMPANY PROFILE
Name:
BIOCYTOGEN PHARMA. H YC1
About:
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4-tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
Sector:
Healthcare
Industry:
Biotechnology
Address:
12 Baoshen South Street, Beijing, China
Website:
https://www.biocytogen.com
ISIN:
CNE100005D27
SYMBOL HISTORY
Purchase End of Day History
for this symbol from Jan 01, 0001
Add to Watchlist
ADD TO WATCHLIST
Please select which Watchlist you would like to add this symbol to:
Watchlist:
DOWNLOAD DATA
Download stock quote history quickly and easily in a variety of formats to suit your needs.
Exchange:
American Stock Exchange
Australian Securities Exchange
Chicago Futures Exchange
Cryptocurrencies
EUREX Futures Exchange
Euronext - Amsterdam
Euronext - Brussels
Euronext - Lisbon
Euronext - Oslo
Euronext - Paris
Foreign Exchange
Frankfurt Exchange
Global Indices
LIFFE Futures and Options
London Stock Exchange
Madrid Stock Exchange
Minneapolis Grain Exchange
Mutual Funds
NASDAQ Stock Exchange
National Stock Exchange of India
New York Board of Trade
New York Stock Exchange
OTC Bulletin Board
Shanghai Stock Exchange
Shenzhen Stock Exchange
Singapore Stock Exchange
Toronto Stock Exchange
Toronto Venture Exchange
Winnipeg Commodity Exchange
Format:
3F VIP Trading
Advanced Get ASCII
AGet ASCII
AIQ Trading Expert Pro
Ami Broker
Ami Broker with Names
Andromeda
ASCII (Intraday)
EzyCharts
FCharts
FCharts (Intraday)
MetaStock ASCII (7 column)
MetaStock ASCII (8 column)
Metastock ASCII (Intraday)
MetaStock ASCII with Names
Personal Stock Streamer
Quicken
SpiffyCharts
Spreadsheet (eg: Excel)
Standard CSV
Stock Screener Pro
SuperCharts ASCII
Wal Data Platinum
Windows on Wallstreet
Period:
End of Day
1 Minute Bars
5 Minute Bars
10 Minute Bars
15 Minute Bars
30 Minute Bars
60 Minute Bars
Zip file
Symbol:
Start Date:
End Date:
Download
FUNDAMENTALS
P/E Ratio:
68.50
Price to Book:
9.63
Price to Sales:
0.97
EBITDA:
382.48M
Shares:
108.27M
Market Cap:
296.67M
TECHNICAL INDICATORS
MA5:
2.57
MA10:
2.55
MA20:
2.58
MA50:
2.48
MA100:
2.10
MA200:
1.57
STO9:
100.00
STO14:
100.00
RSI14:
51.92
MTM14:
0.09
ROC14:
0.03
ATR:
0.13
Week High:
2.74
Week Low:
2.34
Month High:
2.89
Month Low:
2.34
Year High:
2.96
Year Low:
0.59
Volatility:
5.68